- $59.31m
- $52.81m
- $2.03m
Durect up on FDA's 'breakthrough therapy' tag for liver disease treatment
Brief: DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis
Durect Corp Reports Results For The Quarter Ended In January: Earnings Summary
Durect Corp Expected To Post A Loss Of 22 Cents A Share: Earnings Preview
Durect Corp Expected To Post A Loss Of 22 Cents A Share: Earnings Preview
Durect Corp Reports Results For The Quarter Ended In December: Earnings Summary
Durect Corp Expected To Post A Loss Of 33 Cents A Share: Earnings Preview
Brief: Durect Corp Has Regained Compliance With Nasdaq Listing Rule 5550(A)(2) For Continued Listing On Nasdaq Capital Market
Durect Corp Expected To Post A Loss Of 33 Cents A Share: Earnings Preview
Brief: Durect Corporation Announces Topline Results From Phase 2B AHFIRM Trial Of Larsucosterol In Alcohol-Associated Hepatitis With Promising Effect On Mortality
Durect Corp Expected To Post A Loss Of 42 Cents A Share: Earnings Preview
Brief: Durect Corporation Announces Last Patient Last Visit In Phase 2B Ahfirm Trial Of Larsucosterol In Alcohol-Associated Hepatitis
Durect Corp Reports Results For The Quarter Ended In June: Earnings Summary
Durect Corp Expected To Post A Loss Of 51 Cents A Share: Earnings Preview
Durect Corp Expected To Post A Loss Of 51 Cents A Share: Earnings Preview
Brief: DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Brief: DURECT Completes Enrollment In Phase 2b AHFIRM Trial Of Larsucosterol In Alcohol-Associated Hepatitis
Brief: Durect Corp Reports First Quarter 2023 Financial Results And Business Update
Durect Corp Reports Results For The Quarter Ended In March: Earnings Summary